Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 642-648

  King, Rachel N ^a   Lager, Stephanie L ^a  

^a Heartland Health   (United States)

Author keywords

Acid suppression; Antibiotic; Antibiotic associated diarrhea; Antimicrobial; CDI; Clostridium difficile infection; Proton pump inhibitor

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STOMACH SECRETION INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEMOGRAPHY; ELECTRONIC MEDICAL RECORD; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; AGED; ANTACIDS; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 79959690410     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.642     Document Type: Article

References (21)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
2. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 2009;301:954-62.
3. Burdon DW. Clostridium difficile: the epidemiology and prevention of hospital-acquired infection. Infection 1982;10:203-4.
4. Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med 2008;359:1932-40.
5. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
6. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44-50.
7. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in U.S. health care facility inpatients, 2008. Am J Infect Control 2009;37:263-70.
8. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009;48:568-76.
9. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33.
10. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8.
11. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-13.
12. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-5.
13. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772-8.
14. McDonald LC, Owings M, Jernigan JB. Clostridium difficile infection in patients discharged from U.S. short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
15. Elixhauser A, Jhung M. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005. Healthcare cost and utilization project (HCUP) statistical brief no. 50, April 2008. Available from http://www.hcup-us.ahrq.gov/reports/ statbriefs/sb50.pdf. Accessed May 25, 2010.
16. McDonald LC, Coignard B, Dubberke E, et al, for the Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28: 140-50.
17. Howell M, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
18. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010;31:754-9.
19. Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol 2009;6:555-7.
20. Metzger R, Swenson B, Bonatti H, et al. Identification of risk factors for the development of Clostridium difficle-associated diarrhea following treatment of polymicrobial surgical infections. Ann Surg 2010;251:722-7.
21. Bartlett J, Gerding D. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S12-18.